GRF.MC — Grifols, S.A. (Stock)

Price: $9.88 · 1 day: +2.02% · 5 days: +3.63% · 1 month: -0.76% · YTD: -7.66%
As of 2026-10-09 15:35 UTC.

52-week range: $8.43 – $12.21 (currently at 38% of the range).

The read

GRF.MC is in an uptrend, momentum firm. $10 is the level overhead; $9.84 the first support below.

6 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: above
• 50d vs 200d avg: above
• MACD: bullish
• RSI momentum: 57
• 5-day tape: +3.6%

Key levels

Indicators

Next earnings: 2026-07-28.

Latest GRF.MC news

• Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research — The global autoimmune treatment market was valued at USD 176.6 billion in 2025 and is projected to reach USD 321.95 billion by 2034, growing at a 6.9% CAGR, according to Maximize Market Research. Growth is driven by the (PR Newswire, 2026-09-24)
• Grifols says Canada plasma license suspension has no impact on ongoing operations — Grifols, a Spanish drugmaker, stated that Health Canada's suspension of its plasma collection license at its Taylor Avenue facility in Winnipeg has no impact on ongoing operations. The suspension followed regulatory conc (Reuters, 2026-09-24)
• CU Anschutz Researchers Test Drones as a New Way to Deliver Blood Products in Emergencies — Researchers at the University of Colorado Anschutz are studying drone delivery of freeze-dried plasma to critically injured patients, with ongoing trials in Ukraine involving military personnel. Early findings from 26 pa (PR Newswire, 2026-09-23)
• Fewer Blood Components Transfused with fibryga® Than Cryoprecipitate, Secondary Analysis of Prespecified FIBRES Subgroups Reports — A prespecified secondary analysis of the FIBRES trial, published in the Journal of Cardiothoracic and Vascular Anesthesia, showed that fibryga (fibrinogen [human]) significantly reduced 24-hour allogeneic blood-product t (PR Newswire, 2026-09-09)
• US FDA approves first freeze-dried plasma product for use — The U.S. Food and Drug Administration approved Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product in the United States, granting a biologics license to Vascular Solutions, a subsidiary of Teleflex (TFX.N). (Reuters, 2026-07-29)
• ADLM announces 2026 Top Corporate Supporter Award recipients and thanks them for their essential backing — The Association for Diagnostics & Laboratory Medicine (ADLM) announced the 42 recipients of its 2026 Top Corporate Supporter Award at the ADLM 2026 conference in Anaheim, California. The honorees include major diagnostic (PR Newswire, 2026-07-28)
• Point of Care Diagnostics Market worth $31.46 billion by 2031 | MarketsandMarkets™ — The global Point of Care Diagnostics Market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, representing a compound annual growth rate of 8.8%, according to a MarketsandMarkets™ forecast (PR Newswire, 2026-07-10)
• Global Pharmacogenomic Testing Service Market to Register Stunning Growth at a CAGR of ~12% by 2034 | DelveInsight — The global pharmacogenomic testing service market is projected to grow from USD 8.1 billion in 2025 to USD 22.4 billion by 2034, representing a compound annual growth rate of approximately 12%, according to a DelveInsigh (PR Newswire, 2026-07-09)

Explore more

Interactive GRF.MC chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs